Quantum Dog 7

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Aktiivinen ainesosa:

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Saatavilla:

Intervet UK Ltd

ATC-koodi:

QI07AI02

INN (Kansainvälinen yleisnimi):

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Valtuutuksen tilan:

Expired

Valmisteyhteenveto

Revised: April 2011
AN: 01739/2010, 01740/2010, 02097/2010
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Quantum Dog 7
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE(S): QUANTITY PER 1 ML DOSE (MINIMUM TITRE)
Freeze-dried fraction: Quantum Dog DA
2
Pi
Live attenuated canine distemper virus, strain N-CDV,
10
3.0
CCID
50
*
Live attenuated canine adenovirus Type 2, strain Manhattan,
10
3.2
CCID
50
*
Live attenuated canine parainfluenzavirus, strain NL-CPI-5,
10
6.0
CCID
50
*
Liquid fraction: Quantum Dog CPV-L
Live attenuated canine Parvovirus, strain NL-35-D, low passage 10
7.0
CCID
50
*
Inactivated _Leptospira canicola_
40 hamster protective doses
Inactivated _Leptospira icterohaemorrhagiae_
40 hamster protective doses
*Cell culture infectious dose-50
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to prevent mortality and clinical signs
due to canine
distemper virus infections, to prevent clinical signs including
leucopenia and reduce
viral shedding caused by canine parvovirus (type 2a) to prevent
mortality and
clinical signs including leucopenia and reduce viral shedding caused
by canine
parvovirus (types 2b and 2c), to reduce mortality and clinical signs
due to canine
adenovirus type 1 infections, to reduce clinical signs and infection
or excretion due
to canine adenovirus type 2 infections, to reduce clinical signs and
infection due to
_Leptospira canicola_ and _icterohaemorrhagiae _and, to reduce
pathological signs of
disease caused by canine parainfluenza virus infections.
Onset of immunity occurs by approximately two weeks after the last
dose of the
Basic Vaccination Scheme. Onset of immunity for the canine parvovirus
component
(type 2b) occurs 7 days after a single dose when animals are
vaccinated from 9
weeks of age.
Page 1 of 5
Revised: April 2011
AN: 01739